Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-900-4520
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees55
OptionableNot Optionable
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) issued its quarterly earnings results on Thursday, November, 1st. The company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.48) by $0.12. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 brokers have issued twelve-month target prices for Corvus Pharmaceuticals' shares. Their predictions range from $15.00 to $17.00. On average, they expect Corvus Pharmaceuticals' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 288.3% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
Press coverage about CRVS stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next several days.
Are investors shorting Corvus Pharmaceuticals?
Corvus Pharmaceuticals saw a increase in short interest in the month of December. As of December 14th, there was short interest totalling 1,128,930 shares, an increase of 43.8% from the November 30th total of 785,077 shares. Based on an average daily trading volume, of 62,602 shares, the days-to-cover ratio is presently 18.0 days. Currently, 5.7% of the shares of the stock are sold short. View Corvus Pharmaceuticals' Current Options Chain.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Forty Seven (FTSV), Innate Pharma (IPHYF), Odonate Therapeutics (ODT), Corium International (CORI), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Eidos Therapeutics (EIDX), Akorn (AKRX), Clementia Pharmaceuticals (CMTA), Evolus (EOLS), Corbus Pharmaceuticals (CRBP), Beyondspring (BYSI), ZEALAND PHARMA/S (ZEAL), MediciNova (MNOV) and ArQule (ARQL).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 67)
- Mr. Leiv Lea, Chief Financial Officer (Age 64)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 56)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 51)
- Mr. Alan C. Mendelson Esq., Sec.
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $4.12.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $118.30 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.
What is Corvus Pharmaceuticals' official website?
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
